In numerous low-income nations, citizens succumb to preventable diseases primarily due to financial limitations that hinder their access to necessary medications. There exists a debate regarding whether pharmaceutical companies should reduce their product prices in these regions. While the rationale behind this perspective is grounded in the desire for increased affordability, I firmly oppose this notion due to the potential deterioration of drug quality, adverse effects on public health, and the rising propensity for self-medication.
First and foremost, pharmaceutical companies allocate substantial resources towards research and development, which can often extend over a year or more, in addition to compliance with the stringent regulations set forth by quality control agencies such as the Standard Organisation of Nigeria (SON). Should these companies be mandated to reduce prices, they may resort to alternative strategies to maintain profit margins, potentially leading to the adulteration of ingredients. This scenario would result in substandard medications, compromising the effectiveness and safety of treatments. Hence, it is crucial for citizens to prioritize the efficacy and safety of pharmaceuticals over mere cost considerations.
Admittedly, implementing price reductions for medications could enhance accessibility and affordability. However, it is essential to recognize that many individuals in low-income communities may lack sufficient education, which could lead to misconceptions regarding drug prescriptions. Consequently, this ignorance could foster a culture of self-medication, wherein patients inadvertently consume overdoses. Such overdoses could prove extremely harmful, particularly if the drugs in question are compromised. Rather than fulfilling their intended purpose of alleviating ailments, these medications could weaken the immune system, rendering the body increasingly vulnerable to incurable diseases – thereby exacerbating the mortality rate and posing an additional burden to governmental health services.
Therefore, although the objective of reducing drug prices in impoverished countries is to enhance affordability, treat curable diseases, and ultimately lower mortality rates, one must consider the myriad of negative repercussions that such a transition could engender. In my view, it is imperative for pharmaceutical companies to prioritize the maintenance of drug quality to prevent the misuse of medications, which could lead to further loss of life.